$1.33
0[0.00%]
At close: May 20
$1.33
0[0.00%]
After Hours: 8:25AM EDT
Marinus Pharma
(NASDAQ:MRNS)Latest News for Marinus Pharma Stock (NASDAQ:MRNS)
Marinus Pharma Stock (NASDAQ: MRNS)
Categories: All
Thursday, May 09, 2024
Wednesday, May 08, 2024
- Marinus Pharmaceuticals Expects That Cash, Cash Equivalents And Short-term Investments Of $113.3M As Of March 31, 2024, Inclusive Of Cost Reduction Plans, Is Expected To Provide Cash Runway Into Q1 Of 2025Benzinga Newsdesk - May 8, 2024, 7:11AM
- Marinus Pharmaceuticals Has Increased 2024 Projected US ZTALMY Product Revenues To $33M-$35M From $32M-$34MBenzinga Newsdesk - May 8, 2024, 7:10AM
- Marinus Pharma Q1 2024 GAAP EPS $(0.68) Misses $(0.66) Estimate, Sales $7.679M Miss $9.125M EstimateBenzinga Newsdesk - May 8, 2024, 7:08AM
Tuesday, May 07, 2024
Monday, April 29, 2024
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis MissVandana Singh - Apr 16, 2024, 2:45PM
- The Latest Analyst Ratings For Marinus PharmaBenzinga Insights - Apr 16, 2024, 1:00PM
- HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price TargetBenzinga Newsdesk - Apr 16, 2024, 10:59AM
Monday, April 15, 2024
- RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3Benzinga Newsdesk - Apr 15, 2024, 2:52PM
- S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In MarchAvi Kapoor - Apr 15, 2024, 2:30PM
- Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Apr 15, 2024, 2:11PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Apr 15, 2024, 12:31PM
- Crude Oil Down 1%; Charles Schwab Sales Top EstimatesAvi Kapoor - Apr 15, 2024, 12:02PM
- Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?Vandana Singh - Apr 15, 2024, 10:13AM
- Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat EarningsAvi Kapoor - Apr 15, 2024, 10:00AM
- Marinus Pharmaceuticals shares are trading lower after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.Benzinga Newsdesk - Apr 15, 2024, 8:46AM
- Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionAvi Kapoor - Apr 15, 2024, 8:19AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Apr 15, 2024, 8:07AM
- Marinus Pharma Reported Prelim ZTALMY (Ganaxolone) Q1 Net Product Revenue of $7.4M-$7.6M, Cash of $113.3MBenzinga Newsdesk - Apr 15, 2024, 7:38AM
- Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Apr 15, 2024, 7:25AM
- Marinus Pharma to Continue Phase 3 RAISE Trial of IV Ganaxolone for Severe Seizure Treatment, Advances with ZTALMY's Successful Launch, Eyes New Drug Application and Optimizes Cash RunwayBenzinga Newsdesk - Apr 15, 2024, 7:04AM
- Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Apr 15, 2024, 6:55AM
Wednesday, April 10, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Thursday, March 07, 2024
- The Medicines And Healthcare Products Regulatory Agency Has Approved The Medicine Ganaxolone As The First Anti-Seizure Medication In The UK To Treat Cyclin-Dependent Kinase-Like 5 Deficiency DisorderBenzinga Newsdesk - Mar 7, 2024, 12:39PM
- Oppenheimer Maintains Perform on Marinus Pharma, Maintains $9 Price TargetBenzinga Newsdesk - Mar 7, 2024, 8:04AM
Wednesday, March 06, 2024
Tuesday, March 05, 2024
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Mar 5, 2024, 4:31PM
- Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings InsightsBenzinga Insights - Mar 5, 2024, 4:25PM
- Marinus Pharma Q4 2023 GAAP EPS $(0.740) Misses $(0.630) Estimate, Sales $7.190M Miss $8.015M EstimateBenzinga Newsdesk - Mar 5, 2024, 4:23PM
- Earnings Scheduled For March 5, 2024Benzinga Insights - Mar 5, 2024, 5:00AM